30 Day Trial

Xtant Medical Reports 4Q15/2015 Revenue

Share:

Xtant Medical announced 4Q15 revenue of US $22.3MM, +14.1% from 4Q14, and 2015 revenue of $86.5MM, +11.4% vs. 2014. Growth is pro forma.

Source: Xtant Medical Holdings, Inc.

 

Within 1Q16, the company announced CE Mark approval for the Aranax™ cervical plate and the Irix-A™ standalone anterior lumbar fusion device, while in 4Q15, Xtant launched the Certex® OCT Spinal Fixation system and announced initial procedures using the Atrix-C Cervical Allograft Interbody Spacer and the Aranax plate.